TCT-606 BIOTRONIK-Safety and Clinical Performance of the Drug Eluting Orsiro Stent in the Treatment of Subjects With Single De Novo Coronary Artery Lesions-II (BIOFLOW-II) – 2 Year Clinical Results

Rafael Ruizsalmeron,Thierry Lefevre,Michael Haude,Karl Stangl,Ton Slagboom,Franzjosef Neumann,Manel Sabate,Jean Christophe Macia,Gert Richardt,Bela Merkely,Javier Goicolea,Johannes Bilger,Dimitar Divchev,Paul Barragan,Stephane Cook,Bernhard Witzenbichler,Stephan Windecker

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY（2017）

引用 0|浏览25

暂无评分

摘要

In this randomized controlled study (RCT) we compare the clinical efficacy of the Orsiro Hybrid Drug Eluting Stent (Orsiro) with the Xience Prime™ Everolimus Eluting Stent (Xience) at 2 years in the complete study population as well as in the diabetic and small vessel subgroups, which are known to

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要